IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancer. Spolverato G, Fassan M, Scarpa M, Stepanyan A, et al. Br J Surg 2023;110:1490-1501.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Spolverato G, Fassan M, Scarpa M, Stepanyan A, et al. IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancer. Br J Surg 2023;110:1490-1501.
PMID: 37478362